The effectiveness of ulinastatin and methylprednisolone in treating pathological changes in mice with radiation-induced lung injury (RILI) was evaluated. Forty C57BL/6 female mice received whole-chest radiation (1.5 Gy/min for 12 min) and were randomly allocated into Group R (single radiation, n = 10), Group U (ulinastatin treatment, = 10), Group M (methylprednisolone treatment, = 10), or Group UM (ulinastatin and methylprednisolone treatment, = 10). Another 10 untreated mice served as controls (Group C). Pathological changes in lung tissue, pulmonary interstitial area density (PIAD) and expression levels of transforming growth factor beta 1 (TGF-beta 1) and tumor necrosis factor alpha (TNF-alpha) in lung tissue, serum and bronchoalveolar lavage fluid were determined. Alleviation of pathological changes in lung tissue was observed in Groups U, M and UM. Treatment with ulinastatin, methylprednisolone or both effectively delayed the development of fibrosis at 12 weeks after radiation. Ulinastatin, methylprednisolone or both could alleviate the radiation-induced increase in the PIAD (P < 0.05 or P < 0.01). Treatment with ulinastatin, methylprednisolone or both significantly reduced the expression of TNF-alpha, but not TGF-beta 1, at 9 weeks after radiation compared with Group R (P < 0.01). Ulinastatin and/or methylprednisolone effectively decreased the level of TNF-alpha in lung tissue after RILI and inhibited both the inflammatory response and the development of fibrosis.
[1]Canc Hosp Jilin Prov, Intens Care Unit, Changchun 130021, Peoples R China.
[2]Jilin Univ, Bethune Hosp 1, Dept Nephrol, Changchun 130021, Peoples R China.
(8.0+极速模式)